Bohui Innovation(300318)2025-01-20 09:40Financial Performance - The company expects a net profit attributable to shareholders of between RMB 8.5 million and RMB 12.7 million for 2024, a significant recovery from a loss of RMB 24.93 million in the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between RMB 10.8 million and RMB 15 million, compared to a loss of RMB 27.66 million in the same period last year[3] - The expected non-recurring losses for 2024 are approximately RMB 2.3 million, primarily from government subsidies and related compensations, contrasting with non-recurring gains of RMB 2.73 million in the previous year[6] Market Conditions - The decline in operating income is attributed to weakened demand in the blood products market, with sales of human albumin and intravenous immunoglobulin products decreasing year-on-year[5] Cost Management - The company has implemented cost control measures and lean management, resulting in an increase in the gross profit margin of blood products compared to the previous year[5] Business Operations - The company did not experience significant business or debt restructuring in the current reporting period, unlike the previous year which impacted net profit[5][6] - The financial data presented is preliminary and has not been audited, with detailed financial results to be disclosed in the 2024 annual report[7]